Future Farm Technologies (CSE: FFT) (OTC PINK: FFRMF) is a Canadian public company that, following its merger with High Purity Natural Products, is now a leading supplier of top quality health and wellness products, including those made from hemp, to meet the burgeoning demand in the U.S. and global markets.
Future Farm’s seasoned management team, now joined by the High Purity Natural Products management team, brings a deep understanding of manufacturing, formulation, marketing, sales and operations with the financial and regulatory expertise needed to become a significant participant in the rapidly growing market for health and wellness products made from hemp and other plants.
Future Farm Technologies empowers high-quality natural and organic health and wellness brands globally.
Future Farm and its subsidiaries have a seasoned management team that bring a deep understanding of manufacturing, formulation, marketing, sales and operations with the financial and regulatory expertise needed to become a significant participant in the rapidly growing market for health and wellness products made from hemp and other plants.
Acquisitions and capital investment will fuel the continued growth of Future Farm to a cash flow positive, scalable business with multiple revenue streams.
Meet our Family of Companies
High Purity Natural Products
Based in New England since 2017, High Purity Natural Products offers a comprehensive selection of contract manufactured and white label hemp products and is committed to providing the highest quality products, including THC-free, full- and broad-spectrum CBD tinctures, lotions, cosmetics, edibles and vapes.
Most recently, HPNP has added hand sanitizer (available with or without CBD) and Third Party Logistics (3PL) services.
CEPG has secured an industrial hemp cultivation license, a cannabis R&D license and a cannabis Micro Grow license from Health Canada. The Cannabis Research License allows for activities that can include but are not limited to, importation of genetics from around the world, in vivo and in vitro studies, clinical trials, plant breeding, cannabis product development, and educational programs.
Equipped with these licenses, CEPG plans enter the cannabis clone, seedling and seed markets, in both federal medical and non‐medical sales. CEPG is positioned to become a distributor of healthy, high quality, low cost cannabis clones, seeds and seedlings, selling to a rapidly emerging consumer base.